Trials / Completed
CompletedNCT02607631
A Study of Pembrolizumab for Patients With Thymic Epithelial Tumor
A Phase II Study of Pembrolizumab for Patients With Thymic Epithelial Tumor Who Progressed After at Least One Previous Regimen of Cisplatin-Containing Chemotherapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- Samsung Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase II single center, open-label, single arm study in patients with advanced thymic epithelial tumors after failure of cisplatin-based combination chemotherapy. Patients will be treated with Pembrolizumab 200 mg every 3 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pembrolizumab | treated with Pembrolizumab 200 mg every 3 weeks |
Timeline
- Start date
- 2015-11-01
- Primary completion
- 2018-02-01
- Completion
- 2018-08-01
- First posted
- 2015-11-18
- Last updated
- 2020-07-09
Source: ClinicalTrials.gov record NCT02607631. Inclusion in this directory is not an endorsement.